Clinical outcome and efficacy of nusinersen in Korean adult patients with 5q spinal muscular atrophy: Nationwide multicenter retrospective study (Feb, 10.1007/s13760-026-02998-x, 2026)

초록

In this published article, the Figs. 1 and 2 were flipped. In addition, the contents of Table 3 were incorrectly published. The complete correct Figs. 1 and 2; Table 3 are given below. The original article has been corrected.. Univariate analysis of factors associated with treatment response and SMA subtype Factors Mean ± SD or percentage p-value CMI (Responder/Non-responder) 18 (10/8) Responder (n = 10) Non-responder (n = 8) Age, onset 1.12 ± 0.77 0.99 ± 0.48 0.591 Sex (Female) 80.0% 50.0% 0.321 Type (3a, %) 30.0% 37.5% 1.000 Department of previous visit, Number 1.80 ± 1.32 1.88 ± 1.25 0.707 Method of administration, fluorescent (%) 80.0% 87.5% 1.000 Score of HFMSE at baseline 11.60 ± 15.44 7.00 ± 15.15 0.107 Scoliosis 80.0% 75.0% 1.000 Type (2/3a) 19 (12/7) Type 2 (n = 12) Type 3a (n = 7) Age, onset 0.84 ± 0.41 2.00 ± 1.53 0.049 Sex (Female) 58.3% 85.7% 0.333 Responder (CMI) (12/6) 58.3% 50.0%* 1.000 Department of previous visit, Number 1.83 ± 1.27 1.86 ± 1.21 0.964 Method of administration, fluorescent (%) 91.7% 57.1% 0.075 Score of HFMSE at baseline 5.67 ± 8.62 15.86 ± 20.72 0.173 Scoliosis 91.7% 42.9% 0.038 Scoliosis surgery 66.7% 85.7% 0.603 CMI, clinically meaningful improvement; SD, standard deviation. Categorical data was assessed using Fisher’s exact test, and continuous data was analyzed using Mann-Whitney U test. *One SMA type 3a patient did not complete the loading dose at data collection. © The Author(s) under exclusive licence to Belgian Neurological Society 2026.